A Study Investigating Oral Semaglutide in People with Open-Angle Glaucoma
NCT06792422 on ClinicalTrials.gov · last registry update 2025-01-24
Recruiting now, toward 126 participants. Due to report August 2028, alongside 21 other tracked readouts that quarter. Primary outcome, as filed: Photopic negative response of the electroretinogram after 6 months. Sponsors move these dates routinely; any movement since this site started watching is listed below.
- Status
- RECRUITING
- Phase
- P4
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Glostrup University Hospital, Copenhagen
- Sponsor type
- Other
- Enrollment
- 126
- Started
- 2025-01
- Primary completion
- 2028-08 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Photopic negative response of the electroretinogram after 6 months
Conditions studied
Primary Open Angle Glaucoma (POAG) · Open-Angle Glaucoma · Glaucoma
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.